Antistaphylococcal activity of bacteriophage derived chimeric protein P128

BMC Microbiology

Volumn 12, Issue , 2012, Pages

  Vipra, Aradhana A ^a   Desai, Srividya Narayanamurthy ^a   Roy, Panchali ^a   Patil, Raghu ^a   Raj, Juliet Mohan ^a   Narasimhaswamy, Nagalakshmi ^a,c   Paul, Vivek Daniel ^a,b   Chikkamadaiah, Ravisha ^a   Sriram, Bharathi ^a  

^a Gangagen Biotechnologies Pvt Ltd   (India)

^b UNIVERSITY OF TORONTO   (Canada)

^c MELAKA MANIPAL MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDE; CHIMERIC PROTEIN; CHIMERIC PROTEIN P128; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; HYBRID PROTEIN; LYSOSTAPHIN; VIRUS PROTEIN;

ARTICLE; BACTERICIDAL ACTIVITY; BROTH DILUTION; COLONY FORMING UNIT; IN VITRO STUDY; INHIBITION KINETICS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SENSITIVE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUPIROCIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS; ANTIBIOTIC RESISTANCE; BACTERIOPHAGE; DRUG EFFECT; HUMAN; HYDROGEL; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; DRUG RESISTANCE, BACTERIAL; HUMANS; HYDROGELS; LYSOSTAPHIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RECOMBINANT FUSION PROTEINS; VIRAL PROTEINS;

EID: 84858725934     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-12-41     Document Type: Article

References (33)

1. Nosocomial and community acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Steinberg JP, Clark CC, Hackman BO, Clin Infect Dis 1996 23 255 259 10.1093/clinids/23.2.255 8842259
2. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Kourbatova EV, Halvosa JS, King MD, Ray SM, White N, Blumberg HM, Am J Infect Control 2005 33 385 391 10.1016/j.ajic.2005.06.006 16153484
3. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Kluytmans J, van Belkum A, Verbrugh H, Clin Microbiol Rev 1997 10 3 505 520 9227864
4. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. Kluytmans J, Mouton J, Yzerman E, Vandenbroucke-Grauls C, Maat A, Maat A, Wagenvoort, Verbrugh H, J Infect Dis 1995 171 216 219 10.1093/infdis/171.1.216 7798667
5. The role of nasal carriage in Staphylococcus aureus infections. Heiman FL, Wertheim, Melles Damian C, Vos Margreet C, van Leeuwen Willem, Alex van Belkum, Verbrugh Henri A, Nouwen Jan L, Lancet Infect Dis 2005 5 12 751 762 10.1016/S1473-3099(05)70295-4 16310147
6. Coagulase negative Staphylococci: role as pathogens. Huebner J, Goldmann DA, Annu Rev Med 1999 50 223 236 10.1146/annurev.med.50.1.223 10073274
7. Isolation of methicillin-resistant coagulase-negative Staphylococci from patients undergoing continuous ambulatory peritoneal dialysis (CAPD) and comparison of different molecular techniques for discriminating isolates of Staphylococcus epidermidis. De Mattos EM, Teixeira LA, Alves VM, Rezenda e Resende CA, da Silva Coimbra MV, da Silva-Carvalho MC, Ferreira-Carvalho BT, Figueiredo AM, Diagn Microbiol Infect Dis 2003 45 1 13 22 10.1016/S0732-8893(02) 00477-7 12573546
8. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, et al. Clin Infect Dis 2001 32 Suppl 2S 114 132
9. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Van Rijen M, Bonten M, Wenzel R, Kluytmans J, Cochrane Database Syst Rev 2008 8 4 D006216
10. Peptidoglycan hydrolases as novel tool for anti-enterococcal therapy. Maliniová L, Piknová M, Prista P, Javorsk P, Current Research, Technology and Education Topics in Applied Microbiology and Microbial Biotechnology. The Formatex Microbiology Book Series Badajoz, Spain: Formatex Research Center, Mendes-Vilas A, 2010 1 463 472
11. Staphylococcal vaccines and immunotherapy: to dream the impossible dream? Projan SJ, Nesin M, Dunman PM, Curr Opin Pharmacol 2006 6 473 479 10.1016/j.coph.2006.04.005 16870507
12. A Review of Antimicrobial Peptides and Their Therapeutic Potential as Anti-Infective Drugs. Gordon YJ, Romanowski EG, Mcdermott AM, Curr Eye Res 2005 30 7 505 515 10.1080/02713680590968637 16020284
13. Lysostaphin Cream Eradicates Staphylococcus aureus Nasal Colonization in a Cotton Rat Model. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ, Antimicrob Agents Chemother 2003 47 5 1589 1597 10.1128/AAC.47.5.1589-1597.2003 12709327
14. Lysostaphin:an antistaphylococcal agent. Kumar JK, Appl Microbiol Biotechnol 2008 80 555 561 10.1007/s00253-008-1579-y 18607587
15. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. Kokai-Kun JF, Chanturiya T, Mond JJ, J Antimicrob Chemother 2009 64 94 100 10.1093/jac/dkp145 19398455
16. Bacteriophage Therapy: Exploiting Smaller Fleas. Deresinski S, Clin Infect Dis 2009 48 1096 1101 10.1086/597405 19275495
17. Therapeutic use of bacteriophages. Soothill JS, Hawkins C, Anggard EA, Harper DR, Lancet Infect Dis 2004 4 544 545 15336219
18. FDA approves use of bacteriophages to be added to meat and poultry products. Lang L, Gastroenterology 2006 131 5 1370 17067600
19. Bacteriophage endolysins-current state of research and applications. Loessner MJ, Curr Opin Microbiol 2005 8 480 487 10.1016/j.mib.2005.06.002 15979390
20. Bacteriophage lytic enzymes: novel anti-infectives. Fischetti VA, Trends Microbiol 2005 13 491 496 10.1016/j.tim.2005.08.007 16125935
21. Lysis of Staphylococcal mastitis pathogens by bacteriophage phi11 endolysin. Donovan DM, Lardeo M, Foster-Frey J, FEMS Microbiol Lett 2006 265 1 133 139 10.1111/j.1574-6968.2006.00483.x 17054440
22. A novel Bacteriophage Tail Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent antistaphylococcal protein. Paul VD, Rajagopalan SS, Sundarrajan S, George SE, Asrani JY, Pillai R, Chikkamadaiah R, Durgaiah M, Sriram B, Padmanabhan S, BMC Microbiol 2011 11 226 10.1186/1471-2180-11-226 21985151
23. Methods for determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. National Committee for Clinical Laboratory Standards, Approved Guideline M26-A. NCCLS, Wayne, PA 1999
24. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus. Kusuma CM, Kokai-Kun JF, Antimicrob Agents Chemother 2005 49 3256 3263 10.1128/AAC.49.8.3256-3263.2005 16048934
25. Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against Gram-positive clinical isolates. Petersen PJ, Wang TZ, Dushin RG, Bradford PA, Antimicrob Agents Chemother 2004 48 739 746 10.1128/AAC.48.3.739-746.2004 14982758
26. Methods for Determining the Composition of Nasal Fluid by X-Ray Microanalysis. Vanthanouvong V, Roomans GM, Microsc Res Tech 2004 63 2 122 128 10.1002/jemt.20020 14722910
27. Virulence determinants in Staphylococcus aureus and their involvement in clinical syndromes. Ferry T, Perpoint T, Vandenesch F, Etienne J, Curr Infect Dis Rep 2005 7 420 428 10.1007/s11908-005-0043-8 16225779
28. Development and characterization of a Staphylococcus aureus nasal colonization model in mice. Kiser KB, Cantey-Kiser JM, Lee JC, Infect Immun 1999 67 5001 5006 10496870
29. Update on Clinical Significance of Coagulase-Negative Staphylococci. Kloos WE, Bannerman TL, Clin Microbiol Rev 1994 7 1 117 140 8118787
30. Nasal Carriage as a Source of Staphylococcus aureus Bacteremia Study Group. Eiff CV, Becker K, Machka K, Stammer H, Peters G, N Engl J Med 2001 344 11 16 10.1056/NEJM200101043440102 11136954
31. Evolutionary analyses of Staphylococcus aureus identify genetic relationships between nasal carriage and clinical isolates. Lamers RP, Stinnett JW, Muthukrishnan G, Parkinson CL, Cole AM, PLoS One 2011 6 1 16426 10.1371/journal.pone.0016426 21283661
32. Pathogenesis of Methicillin-Resistant Staphylococcus aureus. Gordon RJ, Lowy FD, Clin Infect Dis 2008 46 Supplement 5 350 359
33. Diversity of Staphylococcal Cassette Chromosome mec Structures in Methicillin-Resistant Staphylococcus epidermidis and Staphylococcus haemolyticus Strains among Outpatients from Four Countries. Ruppé E, Barbier F, Mesli Y, Maiga A, Cojocaru R, Benkhalfat M, Benchouk S, Hassaine H, Maiga I, Diallo A, Koumaré AK, Ouattara K, Soumaré S, Dufourcq JB, Nareth C, Sarthou JL, Andremont A, Ruimy R, Antimicrob Agents Chemother 2009 53 2 442 449 10.1128/AAC.00724-08 19001111